Sequential platinum-based chemotherapy-thoracic radiotherapy in early stage non-small cell lung cancer.

Nick Thatcher; Corinne Faivre-Finn; Fiona Blackhall; Heather Anderson; Paul Lorigan

doi:10.1158/1078-0432.CCR-05-9004

Sequential platinum-based chemotherapy-thoracic radiotherapy in early stage non-small cell lung cancer.

Nick Thatcher, Corinne Faivre-Finn, Fiona Blackhall, Heather Anderson, Paul Lorigan

Division of Cancer Sciences (L5)

Research output: Contribution to journal › Article › peer-review

Abstract

Combined chemoradiotherapy (CTRT) is intended to reduce the risk of local regional recurrence and distant relapse in patients with early stage non-small cell lung cancer (NSCLC). Sequential CTRT allows full doses of each modality while avoiding the additive toxicity that occurs with concurrent therapy. This review will encompass studies in the three main settings where sequential CTRT has been applied in early stage NSCLC: as adjuvant therapy after resection, as neoadjuvant chemotherapy and surgery followed by radiotherapy, and in unresectable stage III disease.

Original language	English
Journal	Clinical Cancer Research
Volume	11
Issue number	13
DOIs	https://doi.org/10.1158/1078-0432.CCR-05-9004
Publication status	Published - 1 Jul 2005

Keywords

therapeutic use: Antineoplastic Combined Chemotherapy Protocols
drug therapy: Carcinoma, Non-Small-Cell Lung
administration & dosage: Cisplatin
Combined Modality Therapy
Dose Fractionation
Drug Administration Schedule
Humans
drug therapy: Lung Neoplasms
Neoadjuvant Therapy

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1158/1078-0432.CCR-05-9004

Cite this

@article{77c3e4c4ca274443b48ce001e4438205,

title = "Sequential platinum-based chemotherapy-thoracic radiotherapy in early stage non-small cell lung cancer.",

abstract = "Combined chemoradiotherapy (CTRT) is intended to reduce the risk of local regional recurrence and distant relapse in patients with early stage non-small cell lung cancer (NSCLC). Sequential CTRT allows full doses of each modality while avoiding the additive toxicity that occurs with concurrent therapy. This review will encompass studies in the three main settings where sequential CTRT has been applied in early stage NSCLC: as adjuvant therapy after resection, as neoadjuvant chemotherapy and surgery followed by radiotherapy, and in unresectable stage III disease.",

keywords = "therapeutic use: Antineoplastic Combined Chemotherapy Protocols, drug therapy: Carcinoma, Non-Small-Cell Lung, administration & dosage: Cisplatin, Combined Modality Therapy, Dose Fractionation, Drug Administration Schedule, Humans, drug therapy: Lung Neoplasms, Neoadjuvant Therapy",

author = "Nick Thatcher and Corinne Faivre-Finn and Fiona Blackhall and Heather Anderson and Paul Lorigan",

year = "2005",

month = jul,

day = "1",

doi = "10.1158/1078-0432.CCR-05-9004",

language = "English",

volume = "11",

journal = "Clinical Cancer Research",

issn = "1557-3265",

publisher = "American Association for Cancer Research",

number = "13",

}

TY - JOUR

T1 - Sequential platinum-based chemotherapy-thoracic radiotherapy in early stage non-small cell lung cancer.

AU - Thatcher, Nick

AU - Faivre-Finn, Corinne

AU - Blackhall, Fiona

AU - Anderson, Heather

AU - Lorigan, Paul

PY - 2005/7/1

Y1 - 2005/7/1

N2 - Combined chemoradiotherapy (CTRT) is intended to reduce the risk of local regional recurrence and distant relapse in patients with early stage non-small cell lung cancer (NSCLC). Sequential CTRT allows full doses of each modality while avoiding the additive toxicity that occurs with concurrent therapy. This review will encompass studies in the three main settings where sequential CTRT has been applied in early stage NSCLC: as adjuvant therapy after resection, as neoadjuvant chemotherapy and surgery followed by radiotherapy, and in unresectable stage III disease.

AB - Combined chemoradiotherapy (CTRT) is intended to reduce the risk of local regional recurrence and distant relapse in patients with early stage non-small cell lung cancer (NSCLC). Sequential CTRT allows full doses of each modality while avoiding the additive toxicity that occurs with concurrent therapy. This review will encompass studies in the three main settings where sequential CTRT has been applied in early stage NSCLC: as adjuvant therapy after resection, as neoadjuvant chemotherapy and surgery followed by radiotherapy, and in unresectable stage III disease.

KW - therapeutic use: Antineoplastic Combined Chemotherapy Protocols

KW - drug therapy: Carcinoma, Non-Small-Cell Lung

KW - administration & dosage: Cisplatin

KW - Combined Modality Therapy

KW - Dose Fractionation

KW - Drug Administration Schedule

KW - Humans

KW - drug therapy: Lung Neoplasms

KW - Neoadjuvant Therapy

U2 - 10.1158/1078-0432.CCR-05-9004

DO - 10.1158/1078-0432.CCR-05-9004

M3 - Article

SN - 1557-3265

VL - 11

JO - Clinical Cancer Research

JF - Clinical Cancer Research

IS - 13

ER -

Sequential platinum-based chemotherapy-thoracic radiotherapy in early stage non-small cell lung cancer.

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this